EMA Authorised: Bekemv (Eculizumab) — Amgen Technology (Ireland) UC

View source ↗

Summary

The EMA authorised Bekemv (eculizumab) from Amgen Technology (Ireland) UC for paroxysmal nocturnal hemoglobinuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Bekemv (eculizumab)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal. MAH: Amgen Technology (Ireland) UC. Decision date: 15/01/2026